natgillin/translations-raw huggingface dataset:
The modified IgG4 Fc fragment of claim 1, wherein the hinge region was mutated by the deletion of 1 to 3 continuous or discontinuous amino acid(s) comprising a Cys residue at the 8th position. 
Modificirani IgG4 Fc fragment prema zahtjevu 1, naznačeno time da je zglobna Tegija mutirana putem brisanja od 1 do 3 uzastopne/ih ili neuzastopne/ih aminokiselina sadržeći Cis ostatak na osmom položaju.
An antibody binding to human colony-stimulating factor 1 receptor (CSF-1R), characterized in that the antibody binds to human CSF-1R Extracellular Domain of SEQ ID NO: 64, and does not bind to human CSF-1R fragment delD4 of SEQ ID NO: 65. 
Protutijelo koje se veže na humani CSF-1R, naznačeno time, da varijabilna domena jakog lanca je SEQ ID NO:23 i varijabilna domena slabog lanca je SEQ ID NO:24, ili
The preventive and therapeutic effect of the present compounds on atherosclerosis will be also illustrated by way of the following example. 
Preventivan i terapeutski učinak predloženih spojeva na aterosklerozu će se također prikazati pomoću slijedećeg primjera.
The organic portions are combined, washed with brine (100 ml), dried (MgSO4) and concentrated in vacuo to yield the titled product as a pale yellow solid which is used in the next step without further purification. 
Organski dijelovi se sjedine, isperu sa zas. otopinom NaCI (100 ml), osuše (MgSOxy) i koncentriraju u vakuumu, čime se dobije naslovni proizvod kao blijedo žuta kruta tvar koju se upotrebljava u slijedećem stupnju bez daljnjeg čišćenja.
The composition may be provided in different forms. In one embodiment of the invention, the hedgehog shaped particles are combined with the at least one hydrophobizing agent and/or at least one hydrophilizing agent, and the binder. 
- barem jedno sredstvo za hidrofobiziranje i/ili barem jedno sredstvo za hidrofiliranje, naznačen time da su igličaste čestice sastavljene od materijala odabranog od materijala koji sadrži kalcijev karbonat, saten bijelo i njihove smjese.
angiotensin converting enzyme (ACE) Inhibitor or a pharmaceutically acceptable salt thereof, 
(Hi) - inhibitor enzima pretvaranja angiotenzina (ACE-inhibitor) ili njegova farmaceutski prihvatljiva sol,
The pharmaceutical composition of any one of claims 1 to 10, prepared by wet granulation. 
Farmaceutska kompozicija prema patentnom zahtjevu 10, naznačena time što je sredstvo za vlaženje natrijev lauril sulfat.
forming a tablet by first mixing and then compressing the rifaximin granules with the one or more of an extragranular excipient including a disintegrant. 
- < oblikovanje tableta prvo miješanjem i zatim komprimiranjem granula rifaksimina s jednim ili više ekstragranularnih ekscipijenata koji uključuju sredstvo za razlaganje.
A process for preparing a compound of the general formula (I) or an enantiomer or salt thereof, wherein 
Postupak proizvodnje lijeka, naznačen time, da obuhvaća uporabu spoja opće formule (I):
The system according to claim 1, wherein the arm is made of carbon fibre or titanium. 
Sustav u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje je ručka (26) napravljena od ugljikovog vlakna ili titanija.
The titled compound was prepared analogously to 4-cyano-3-ethoxy-benzenesulfonyl chloride (Intermediate 127c) by replacing bromoethane with 1-bromopentane. 
Naslovni spoj je proizveden analogno 4-cijano-3-etoksi-benzensulfonil kloridu (intermedijat 127c) zamjenom bromoetana s 1-brompentanom.
Determination of the Dissolution of Tablets Comprising Rifaximin t 
Datum objave europske prijave patenta:
The process according to claim 1, which further comprises supplying external heat energy for start-up and/or for maintaining an operating temperature for denoxing the flue gases. 
Postupak prema zahtjevu 1, naznačen time da se dovodi vanjska toplinska energija za pokretanje i/ili za održavanje radne temperature za denitrifikaciju dimnih plinova (A).
The composition of claim 4, wherein said cell is a mesenchymal stem cell, a myoblast, a vascular progenitor cell, a differentiated cell derived from an embryonic stem cell or an induced pluripotent stem cell, an induced pluripotent cell, or a cell that was directly reprogrammed from a fibroblast to a differentiated state. 
Pripravak u skladu s patentnim zahtjevom 4, naznačen time što je navedena stanica mezenhimna matična stanica, mioblast, stanica krvnih žila, diferencirana stanica nastala iz embrionske matične stanice ili inducirane pluripotentne matične stanice, inducirane pluripotentne stanice, ili stanice izravno reprogramirane iz fibroblasta u diferencirano stanje.
The compound of claim 1, where R5 is halo. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R* halo.
The use of the compounds of the formula I as claimed in one or more of claims 1 to 4 for the manufacture of a medicament for the treatment and/or prevention of conditions which may be associated with the metabolic syndrome. 
. Spojevi formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23, namijenjeni upotrebi u liječenju i/ili sprječavanju stanja koja mogu biti povezana s metaboličkim sindromom.
The invention is based on the surprising recognition that if 10 to 60% by weight of sodium chloride and/or potassium chloride are added to the powder mixture to be pelletized in addition to at most 80% by weight of active agent and 10 to 60% by weight of microcrystalline cellulose, pellets with high active ingredient content and very advantageous in shape (approximately spherical) can be produced from the otherwise unpelletizable active agents as well. 
Izum se zasniva na iznenađujućem otkriću da se dodatkom 10 do 50% (težinski) natrijeva klorida i/ili kalijeva klorida praškastoj smjesi koju treba granulirati uz dodatak do najviše 80% (težinski) aktivne tvari i 10 do 60% (težinski) mikrokristalne celuloze, mogu se dobiti granule s visokim sadržajem aktivnog sastojka i odlično oblikovane (približno kuglaste), od aktivne tvari koja se inače ne može granulirati.
Method according to the preceding claims, further comprising the phase of cyclically verifying, after the connection of the load (16) to the network (10), the regular detection of leakage currents by generating al least a test current. 
Postupak u skladu s prethodnim zahtjevima, naznačen time da slijedi faza periodičke provjere, nakon spajanja trošila (16) na mrežu (10), regularno otkrivanje parazitne struje generiranjem struje vrijednosti najmanje ispitne struje.
Particularly, a pharmaceutical composition of the present invention can further comprise at least one additional agent, drug, medicament, antibody and/or inhibitor for treating, ameliorating or preventing an ERR-a mediated disease. 
Farmaceutski pripravak prema zahtjevu 15, naznačen time da nadalje sadrži barem jedno dodatno sredstvo, lijek, medikament, protutijelo i/ili inhibitor za liječenje, ublažavanje ili prevenciju ERR-a posredovane bolesti.
The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine. TECHNICAL FIELD 
Stabilna tekuća formulacija koja sadrži protutijela naznačena time da sadrži od 40 do 1000 mM arginina 1 od 10 do 200 mM metionina.
The compound or salt of claim 17 for use wherein said cancer is a solid tumor, prostate cancer, renal cancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, hematological cancer, lymphoma, leukemia, multiple myeloma, skin cancer, cutaneous T-cell lymphoma or cutaneous B-cell lymphoma. 
Spoj ili sol za upotrebu prema patentnom zahtjevu 23, naznačen time da je navedeni tumor izabran od tumora prostate, tumora bubrega, tumora jetre, tumora želuca, tumora štitnjače, glioblastoma, Karposijevog sarkojema, Castlemanove bolesti, melanoma, kožnog limfoma 'T-stanica (CTCL), kožnog Bell limfoma, Sezaryovog sindroma, mycosis fungoides, akutne limfoblastične leukemije, 1 tumora debelog crijeva.
Z: RZ0, or a non-aromatic heterocyclic ring which may be substituted with one or more groups selected from Group GA; 
ne-aromatic heterociklički prsten koji može biti supstituiran s jednom ili više skupina izabranih iz grupe koju čine C1-6 linearni ili razgranati alkil, -CO-C1-6 linearni ili razgranati alkil, okso, -CO-RZB i benzil;
Thought disorder describes an underlying disturbance to conscious thought and is classified largely by its effects on speech and writing. 
Poremećaj razmišljanja opisuje smetnje svjesnog razmišljanja i uvelike je klasificiran svojim učincima na govor i pisanje.
Process (j) reacting a compound of the Formula VIII: wherein R1, R2, R3, X1, and m have any of the meanings defined in claim 1 except that any functional group is protected if necessary and Lg is a displaceable group as hereinbefore defined, with an aniline of the Formula IX: wherein R5 and n have any of the meanings defined in claim 1 except that any functional group is protected if necessary, and wherein the reaction is conveniently performed in the presence of a suitable acid; 
VII u kojoj R*, Rž, R', X', ni m imaju bilo koje od značenja definiranih u zahtjevu 1, samo što je bilo koja od funkcionalnih skupina po potrebi zaštićena, R' skupina je skupina R' u skladu sa definicijom u tekstu uz napomenu da je bilo koja T skupina zamijenjena sa Lg, i Lg je izlazna skupina (na primjer kloro ili bromo), i spoja sa formulom TH, u kojoj je T u skladu sa gornjom definicijom, uz napomenu da je bilo koja od funkcionalnih skupina, po potrebi, zaštićena;
Preferred embodiments of the invention thus include: 
Broj objave europskog patenta:
Item 2. The building panels as in item 1, wherein the backing layer (4) comprises at least three core grooves (19) spaced horizontally and inwardly from the locking system at one pair of opposite edges. 
Podne ploče prema zahtjevu 1, naznačene time da nosivi sloj (4) sadrži barem tri utora jezgre (19) koji su razmaknuti vodoravno i prema unutra od sustava za zaključavanje na jednom paru suprotnih rubova.
The pharmaceutical composition or the pharmaceutical dosage form according to embodiment 12, wherein the depression is selected from the group consisting of major depressive disorder, unipolar depression, treatment-refractory depression, resistant depression, anxious depression and bipolar depression. 
Farmaceutski sastav ili farmaceutski oblik doziranja za upotrebu prema zahtjevu 11, pri čemu je depresija odabrana iz grupe koja obuhvaća veliki depresivni poremećaj, unipolarnu depresiju, liječenje refraktorne depresije, rezistentnu depresiju, anksioznu depresiju i bipolarnu depresiju.
means for securing an inseparable connection of the base unit 3 press fit to the collapsible beverage container 2 in the form of three or more annular elevations, cooperating with an annular elevation on the neck of the container 2. 
- > sredstvo za učvršćenje nerastavljivog spoja osnovne jedinice 3, koja točno pristaje na sklopivi spremnik za piće 2 u obliku tri ili više prstenastih povišenih elemenata koji djeluju zajedno s prstenastim povišenim elementom na vratu spremnika 2.
A method in accordance with claim 1 or claim 2, wherein diabetes is Type 2 diabetes. 
Pripravak u skladu sa zahtjevom 35, naznačen time, da služi za liječenje ili prevenciju dijabetesa tipa 2.
is CD3; and is CH3; for use in a method of treatment or diagnosis of the human or animal body. 
uz uvjet da kada R1 je CH3, tada R2 nije CH3; za uporabu u liječenju bolesnika koji pati od ili koji je podložan dijabetičkoj neuropatskoj boli.
eluting said furin polypeptide or truncated furin polypeptide from the mixed cation exchange/hydrophobic interaction resin, 
(B) Eluiranje navedenog furin polipeptida ili skraćenog furin polipeptida iz mješavine smole za kationsku razmjenu / hidrofobnu interakciju,
The vial adapter element according to claim 2, wherein said body comprises a conical flange that extends inwards from said rim. 
Adapter za bočicu (10) sukladno zahtjevu 2, naznačen time da navedeno tijelo (17) ima konusnu prirubnicu koja se pruža s navedenog ruba prema unutra (18).
Capsule according to claim 1 or 2, characterized in that as a result of the displacement of the actuation element (5; 5e, 5s), at least one flow passage (S3) is released for entry of the flow inside the accumulation chamber (6). 
Kapsula u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da kao rezultat pomicanja elementa za pokretanje (5; Se, 5s), najmanje jedan protočni kanal ($3) može se osloboditi za ulaz toka unutar akumulacijske komore (6).
A combination according to claim 5 wherein the B2 agonist is formoterol fumarate. 
Kombinacija sukladno patentnom zahtjevu 5, naznačena time, da je B2 agonist formoterol fumarat.
It should carry a "simple message" of authenticity which can be rapidly and easily checked by the "man on the street", independent of his level of education; 
Treba nositi Jednostavnu poruku" autentičnosti koju "slučajni prolaznik", neovisno o svojoj obrazovnoj razini, može brzo 1 lako provjeriti; ii)
3-(trans-2-((R)-4-cyclobutyl-3-methylpiperazine-1-carbonyl)cyclopropyl)benzamide, diastereomeric mixture; and pharmaceutically acceptable salts thereof or mixtures thereof. 
3-(trans-2-((R)-4-ciklobutil-3-metilpiperazin-1-karbonil)ciklopropil)benzamida, dijastereomerna smjesa; 1 njihove farmaceutski prihvatljive soli ili njihove smjese.
the H atom indicated is in the exo position; 
pi R2 naznačen time što: prikazani H atom je u položaju exo;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A compound represented by formula (I), a pharmaceutically acceptable salt or a hydrate thereof: wherein, in the formula (I) 
Spoj predstavljen formulom (1), farmaceutski prihvatljiva sol ili njihov hidrat: iFormula 11 pri čemu, u formuli (1)
identifies a maximum in said cross-covariance values as corresponding to a time of arrival of said reflected pulse of output ultrasonic vibrations. 
(ii) identificira maksimum u navedenim vrijednostima unakrsne kovarijance kao odgovarajući vremenu dolaska navedenog trenutnog impulsa izlaza ultrazvučnih vibracija ili
wherein the metadata comprises the upmix parameters and the mixing parameters. A computer program product comprising a computer-readable medium with instructions for performing the method of any of examples 1-23 and 27-30. 
Računalni programski proizvod, naznačen time što sadrži računalno čitljivi medij s uputama za provođenje postupka u skladu s bilo kojim od patentnih zahtjeva 1-11, kada se navedeni program izvršava na računalu.
The method of claim 5, wherein the compound of Formula (I′) is one or more of the following compounds: 
Spoj formule (T) iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, pri čemu je navedeni spoj jedno ili više od sljedećih spojeva:
the chemical modification comprises an end blocking modification of a 5' untranslated region of the mRNA; 
(ii) kemijska modifikacija podrazumijeva modifikaciju tipa bloka kraja 5' netranslatirajuće regije IRNK;
An antitumor agent for solid cancers, wherein a combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 is administered, using a reduced amount of trifluridine, at a dose in the range of 35 to 70 mg/m2/day, and irinotecan hydrochloride hydrate is administered at a dose in the range of 45 to 144 mg/m2/day. 
HR P20182145 T1 PATENTNI ZAHTJEVI Antitumorni agens za primjenu u liječenju solidnih tumora, gdje kombinirani lijek koji sadrži trifluridin i tipiracil hidroklorid u molarnom odnosu od 1:0.5 je administriran, primjenjujući smanjenu količinu trifluridina, u dozi u opsegu od 35 do 70 mg/m"/dan, i irinotekan hidroklorid hidrat je administriran u dozi u opsegu od 45 do 144 mg/m'/dan.
The composition for use according to claim 23, wherein the subject is relapsed or refractory to a prior tyrosine kinase inhibitor or chemotherapeutic agent. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je subjekt u relapsu ili je refraktoran na prethodni inhibitor tirozin kinaze ili kemoterapijski agens.
The method of claim 25, wherein therapeutically effective amount of crenolanib or a salt thereof is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed hematologic malignant proliferative disease pediatric patient, to maintain remission, or a relapsed/refractory hematologic malignant proliferative disease pediatric patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove soli osigurana kao jedini agens ili u kombinaciji s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije ili subjektu s relapsiranom ili refraktornom akutnom mijeloičnom leukemijom (AML).
The composition of claim 27, the kit of claim 28, or the use of any one of claims 35 to 39, wherein the second pharmaceutical agent is selected from the group consisting of: an anti-CD20 antibody; an anti-CD40 antibody; an anti-Her2 antibody; an anti-EGFR antibody; and anti-VEGF antibody; an anti-CD52 antibody; an anti-CD33 antibody; a H2 receptor agonist; Bacille Calmette-Guerin; thalidomide; Lenalidomide; a proteasome inhibitor; a combination of cyclophosphamide, vincristine and prednisone; a combination of cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone; a cytokine; interferon a; interferon Y; 5-fluorouracil; an anti-retroviral compound; a tyrosine kinase inhibitor; and Decitabine. 
Sastav prema patentnom zahtjevu 26, naznačen time, da se drugi farmaceutski agens odabire iz skupine koja sadrži: anti-CD20 antitijelo; anti-CD40 antitijelo; anti-Her2 antitijelo; anti-EGFR antitijelo; i anti- VEGF antitijelo; anti-CD52 antitijelo; anti-CD33 antitijelo; H2 receptor agonist; bacil Calmette-Guerin; talidomid; Lena-lidomid; inhibitor proteasoma; kombinaciju ciklofosfamida, vinkristina i prednisona; kombinaciju ciklofosfamida, hidroksidoksorubicina, vinkristina i prednisona; citokin, interferon a; interferon y; 5-fluorouracil; anti-retrovirusni spoj; inhibitor tirozin kinaze i Decitabin.
means (1604) configured to modulate the signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; and means (1605) configured to transmit the signal frame via a signal, 
sredstva za moduliranje (S1705) okvira signala pomoću OFDM metode; i sredstva za odašiljanje (S1707) moduliranog okvira signala.
The composition of claim 3 wherein the cognate acid of the acid salt has a pKa of 4.7 or less than 4.7. 
Sastav prema patentnom zahtjevu 3, naznačen time, da odgovarajuća kiselina kiselinske soli ima pK,-vrijednost od 4,7 ili manju od 4,7.
The method of claim 2 wherein the compound is administered orally via drinking water or as an additive to feedstuffs. 
Spoj za uporabu prema zahtjevu 4, naznačen time, da se spoj primjenjuje oralno preko vode za piće ili kao dodatak prehrambenim sastavima.
A compound selected from Compound 32 and Compound 33: or a pharmaceutically acceptable salt thereof. 
OI N H 14. Spoj naznačen time da se bira od spoja 32 i spoja 33:
In one embodiment, the at least one pharmacologically active agent is a polypeptide. In one embodiment, the at least one pharmacologically active agent comprises an antigen binding site (e.g., an antigen binding site derived from a non-BBB transmigrating antibody). 
Vezivna molekula u skladu s patentnim zahtjevom 1, naznačena time što je najmanje jedno farmakološki aktivno sredstvo polipeptid, po mogućnosti gdje najmanje jedno farmakološki aktivno sredstvo sadrži mjesto vezanja antigena, poželjnije gdje je mjesto vezanja antigena dobiveno iz protutijela koje se ne veže na TMEM30.
Figure 8 is a plan view of the sheet metal strip on termination of the drawing stage, 
je pogled s gornje strane na limenu metalnu traku na završetku faze izvlačenja, slika 9
a mutated form of the wt human FAPa on the cell surface, wherein the amino acid residues at positions 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 and 362 are mutated to the corresponding amino acid residues of the wt rodent FAPa; and 
(ii) mutirani oblik ljudskog FAPa divljeg tipa na površini stanice, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 1 362 mutirani u odgovarajuće aminokiselinske ostatke FAPa. glodavca divljeg tipa; i
A method according to claim 9, wherein the ddRNAi agent or the ddRNAi construct inhibits expression of at least the HBV polymerase gene. A pharmaceutical composition comprising a ddRNAi agent according to claim 1 and a pharmaceutically acceptable carrier or diluent. A method of treating acute or chronic HBV infection in a subject comprising administering to said subject a therapeutically effective amount of a ddRNAi expression construct of claim 8, wherein the ddRNAi expression construct inhibits expression of one or more target sequences in one or more HBV genes. 
Agens za ddRNKi ili ddRNKi ekspresijska kaseta ili ddRNKi ekspresijski konstrukt za upotrebu prema bilo kojem od patentnih zahtjeva od 11 do 13, gdje ddRNKi agens ili ddRNKi ekspresijska kaseta ili ddRNKi1 ekspresijski konstrukt inhibira ekspresiju barem gena za HBV polimerazu. Farmaceutski sastav koja sadrži ddRNKi agens prema bilo kojem od patentnih zahtjeva od 1 do 8 ili ddRNK ekspresijsku kasetu prema patentnom zahtjevu 9 ili ddRNKi ekspresijski konstrukt prema patentnom zahtjevu 10 i farmaceutski prihvatljiv nosač ili razrjeđivač.
The crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione of claim 14, wherein the X-ray powder diffraction pattern further comprises peaks at 17.5, 20.5, 24 and 26 degrees 2θ. 
Kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion u skladu s patentnim zahtjevom 14, naznačen time što mu uzorak difrakcije rendgenskih zraka na prahu dodatno sadrži pikove na 17,5, 20,5, 24 i 26 stupnjeva 2θ.
Method according to any of the claims 1, wherein the aqueous solution in step c) of the present method comprises 30-50% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 9, naznačen time da vodena otopina u koraku c) sadrži najmanje 30 % v/v acetonitrila kao organskog otapala koje se miješa s vodom.
The transmission method according to claim 9, wherein when one cluster is allocated to the communication partner apparatus, the generating includes signaling the resource allocation information using only the available bits in the resource allocation field. 
Postupak prijenosa prema jednom od zahtjeva 9 do 13, naznačen time da kad se dodjeljuje jedan klaster, podatak o dodjeli resursa signalizira se korištenjem dostupnih bitova u polju dodjele resursa isključivo.
Those two goals are: to decrease copper leaching and to increase effectiveness against wood destroying organisms (wood decay fungi, insects, and termites). 
Ta dva cilja su: smanjivanje ispiranja bakra i povećavanje djelotvornosti protiv organizama koji uništavaju drvo (gljivice koje uzrokuju propadanje drva, kupci, i termiti).
The particle of claim 12, wherein the immunogen can elicit an immune response in vivo against: 
Čestica u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što imunogen može izazvati imunosni odgovor in vivo protiv: